Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies
| Autor: | Maurice B, Bizino, Ingrid M, Jazet, Huub J, van Eyk, Patrick C N, Rensen, Petronella H, Geelhoed-Duijvestijn, Aan V, Kharagjitsingh, Elisabeth H M, Paiman, Johannes W, Smit, Hildebrandus J, Lamb |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Blood Glucose Male Asia Adolescent Injections Subcutaneous Glycemic Control Drug Administration Schedule Placebos Young Adult Humans Hypoglycemic Agents Insulin Aged Netherlands Randomized Controlled Trials as Topic Retrospective Studies Glycated Hemoglobin Liraglutide Middle Aged Metformin Europe Treatment Outcome Diabetes Mellitus Type 2 Drug Therapy Combination Female Follow-Up Studies |
| Zdroj: | Acta diabetologicaReferences. 58(4) |
| ISSN: | 1432-5233 |
| Popis: | Data on the effect of liraglutide on glycemic endpoints in people with T2DM using multiple daily insulin injections (MDI) are scarce, especially in the context of ethnicity.This is a secondary analysis of the placebo-controlled randomized clinical "MAGNA VICTORIA" trials in Western European (WE) and South Asian (SA) people with T2DM. Participants had inadequate glycemic control despite using metformin and/or sulfonylurea derivatives and/or insulin. Participants were assigned to liraglutide (1.8 mg) or placebo for 6 months, in addition to standard care. The primary endpoint number of participants reaching target HbA1c was compared for liraglutide versus placebo in the complete dataset and MDI-treated participants using Chi-square test. Liraglutide's efficacy in WE and SA was compared using a generalized linear model.Forty-five subjects were randomized to liraglutide and 51 to placebo. In each group, one participant did not complete the study. Liraglutide-treated patients reached target HbA1c more frequently: 23/45 (51%) vs 11/51 (22%), relative probability 2.4 (1.3-4.3), p = 0.002. Subgroup analysis in 43 MDI participants showed that the proportion reaching target HbA1c using liraglutide was significantly higher than in placebo: 9/22 (41%) vs 1/21 (5%), p = 0.005. There was no difference between WE and SA in terms of liraglutide efficacy (p = 0.18).Liraglutide treatment resulted in increased chance of reaching target HbA1c as compared to placebo. Liraglutide efficacy was sustained in participants using MDI regimens and those of SA descent. Liraglutide should be considered for T2DM people with inadequate glycemic control despite MDI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink